Paper Details

  1. Home
  2. Paper Details

Optimized combination therapies with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or entecavir may be effective for chronic hepatitis B patients with a suboptimal response to ADV monotherapy.

Author: ChongYutian, GaoZhiliang, JieYusheng, LiXiangyong, LiXinhua, LinGuoli, ShiHong, WuYuankai, YouXu, ZhangMin

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study aims to identify high-risk factors for chronic hepatitis B patients who have a suboptimal response to adefovir dipivoxil (ADV) monotherapy and to assess the efficacy of combination therapies for patients with a suboptimal response to ADV.
Paper Details　
Original Abstract of the Article :
To identify high risk factors in chronic hepatitis B (CHB) patients for suboptimal response to adefovir dipivoxil (ADV) monotherapy, and to assess the efficacy of optimized therapy combining ADV with lamivudine (LAM), telbivudine (LdT), or entecavir (ETV) in patients with a suboptimal response to AD...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723882/

データ提供：米国国立医学図書館（NLM）

Optimizing Chronic Hepatitis B Treatment with Combination Therapy

This study delves into the field of hepatology, exploring the potential of combination therapies for chronic hepatitis B (CHB) patients who have suboptimal responses to adefovir dipivoxil (ADV) monotherapy. The authors investigated the efficacy of combining ADV with lamivudine (LAM), telbivudine (LdT), or entecavir (ETV). Their findings suggest that optimized combination therapies with ADV and LAM, LdT, or ETV may be effective for CHB patients with a suboptimal response to ADV monotherapy. The study highlights the importance of tailoring treatment strategies based on individual patient factors and response to therapy. This research contributes to the ongoing efforts to optimize CHB management and achieve durable viral suppression.

Combination Therapy: A Powerful Tool for CHB Management

The study's findings emphasize the value of combination therapy for CHB patients who have not achieved optimal responses to monotherapy. Tailoring treatment regimens based on individual patient characteristics and response to therapy could lead to improved outcomes, including sustained viral suppression and improved liver function.

Chronic Hepatitis B: A Long-Term Challenge

CHB is a chronic and potentially life-threatening liver infection. This study underscores the importance of ongoing research and innovation in CHB management. Finding new and effective therapies, including optimized combination regimens, is crucial for improving the lives of millions of individuals living with CHB.

Dr.Camel's Conclusion

This study is like a wise old camel guide, offering a map to navigate the complex terrain of chronic hepatitis B treatment. By considering combination therapy and tailoring treatment strategies, we can optimize care for CHB patients and enhance their chances of achieving sustained viral suppression and improved liver health.
Date :
  1. Date Completed 2016-02-17
  2. Date Revised 2020-09-30
Further Info :

Pubmed ID

26885037

DOI: Digital Object Identifier

PMC4723882

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.